Skip to content

Corporate brand

Unclaimed

Swiss contract research organization specializing in recombinant antibody production in CHO cells.

Last updated September 1, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

evitria AG is a Swiss contract research organization specializing in recombinant antibody production in CHO cells. It is located in Zurich, Switzerland, and is part of the Atlas Life Sciences Group, owned by Patricia Industries. The company offers custom antibody production services including recombinant antibodies, bispecific antibodies, afucosylated antibodies, Fc-silenced antibodies, and high-throughput production, serving biotech and pharma clients worldwide.

History

evitria is an established, global antibody expression service provider located in Zurich, Switzerland. It is specialized in CHO-based transient expression of antibodies and other proteins. The company has performed over 140,000 transfections and expressed and purified more than 23,000 antibodies for clients from the Americas, Europe, Asia and Australia. Since 2010, it has performed over 140,000 transfections and purified more than 20,000 antibodies. evitria is part of the Atlas Life Sciences Group, owned by Patricia Industries.

Products and positioning

  • Recombinant Antibody Expression Service

    Standard IgG production service.

  • Bispecific Antibody Production Service

    Dual-targeting formats.

  • Afucosylated Antibody Service

    Enhanced ADCC and increased effector function.

  • Fc-Silenced Antibody Production Service

    Reduced effector function.

  • High-Throughput Antibody Production Service

    Parallel expression of a large number of constructs.

  • Other Recombinant Protein Expression Service

    Non-antibody soluble proteins, such as antigens or alternative scaffolds.

  • eviCHO Expression Kit

    Ready-to-use CHO expression system for transient protein expression in CHO-K1 cells.

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/evitria-ag · Editorial policy · How profiles are compiled